FiercePharma

New Data Show Greater Bone Mineral Density Gains With Prolia(R) (Denosumab) Compared With Zoledronic Acid

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. Please see the Important Safety Information below. Important Safety Information (U.S.) Prolia is ...
Business Insider

European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. Please see the Important Safety Information below. EU Important EU Product Information Calcium and Vitamin D ...
Insurancenewsnet.com

New Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. Please see the Important Safety Information below. Important Safety Information (U.S.) Prolia is ...
FierceBiotech

FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture

Given As An Injection Every Six Months, Prolia Reduced Risk Of Fracture At The Spine, Hip And Other Sites THOUSAND OAKS, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) today ...